Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Active not recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 8Gastrointestinal 5Head & Neck 4Genitourinary 3Breast 2Endocrine 1Dermatologic 1CNS 1

Conditions

Squamous Cell Carcinoma of Head and Neck 1Neoplasms 1Melanoma 1Carcinoma, Non-Small-Cell Lung 1

Interventions

pembrolizumab 161Nivolumab 133Ipilimumab 78Cyclophosphamide 47Specimen Handling 43Magnetic Resonance Spectroscopy 39cemiplimab 35Biopsy 31fludarabine 29trametinib 24relatlimab 24binimetinib 23Interleukin-2 22fludarabine phosphate 21dabrafenib 20atezolizumab 19Radiotherapy 19Opdualag 19aldesleukin 18Radiosurgery 18CTLA-4 Antigen 18encorafenib 17Blood Specimen Collection 17avelumab 14Immunoglobulin G 14Disulfides 13lifileucel 11lenvatinib 11Bevacizumab 11Paclitaxel 10

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
budigalimab × Dermatologic × 1 year × Clear all
NCT02988960 2026-01-09

A Study of ABBV-927 and ABBV-181, an Immunotherapy, in Participants With Advanced Solid Tumors

AbbVie

Phase 1 Active not recruiting
163 enrolled
DermatologicHead & NeckThoracic

Squamous Cell Carcinoma of Head and Neck, Carcinoma, Non-Small-Cell Lung, Melanoma, Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡